National MS Society Launches Survey to Assess Economic Impact of MS
The National Multiple Sclerosis Society, together with the Lewin Group, has launched a survey to assess the economic…
Articles by Joana Carvalho, PhD
#MSVirtual2020 – Tysabri Better Than Other DMTs at Easing Some MS Symptoms
Tysabri (natalizumab) is superior to other disease-modifying therapies (DMTs) at improving balance and vision, easing…
#MSVirtual2020 – 13-year Data Find Tecfidera Safe, Reduces RRMS Relapses
Long-term treatment with Tecfidera (dimethyl fumarate) continues to be safe and effective at reducing the frequency of relapses and…
#MSVirtual2020 – Long-term Aubagio Use Seen to Lower Relapse Risk for Children
Continuous treatment with Aubagio (teriflunomide) can safely lower the risk of relapses and disability progression in children with relapsing…
#MSVirtual2020 – Cognitive Problems in Children With MS Can Persist Into Adulthood
Cognitive problems can persist into adulthood in people whose multiple sclerosis (MS) began in childhood or adolescence, and are…
#MSVirtual2020 – High-efficacy DMTs More Effective at Slowing Retina Atrophy in RRMS Patients, Study Finds
Compared to low-efficacy disease-modifying therapies (DMTs), high-efficacy medications are more effective at slowing the loss of nerve cells making up…
#MSVirtual2020 – Lesions First Seen on Nerves of GI Tract in Mouse Model of MS
Before signs of neurodegeneration in the brain and spinal cord are evident in mice with experimental autoimmune encephalomyelitis (EAE)…
#MSVirtual2020 – Relapses During Pregnancy More Likely on Higher Efficacy DMTs
Women with relapsing-remitting multiple sclerosis (RRMS)Â using moderate- or high-efficacy disease-modifying therapies (DMTs) before conceiving are more likely to…
#MSVirtual2020 – Long DMT Exposure May Delay Disability Progression, Wheelchair Use
Longer exposure to disease-modifying therapies (DMTs) may delay disability progression and the time until people with primary progressive…
#MSVirtual2020 – Low Rituximab Doses Are Safer, as Effective as Higher Ones
Low doses of rituximab, an anti-inflammatory medication used off-label to treat multiple sclerosis (MS), are safer and as…
#MSVirtual2020 – Tolebrutinib Prevents Myelin Loss in Mouse Model of MS-like Demyelination
Tolebrutinib (SAR442168), an investigational oral BTK inhibitor to treat relapsing forms of multiple sclerosis…
#MSVirtual2020 – GeNeuro’s Temelimab Found Safe When Given Alongside Rituximab
Temelimab, GeNeuro’s investigative treatment for multiple sclerosis (MS), showed a favorable safety profile when given alongside…
#MSVirtual2020 – New Safety, Efficacy Data on Mavenclad, Rebif and Evobrutinib on Way
EMD Serono will present new data from programs assessing the efficacy and safety of Mavenclad (cladribine) and Rebif…
#MSVirtual2020 – ATA188 Safe, Early Efficacy Seen in Progressive MS Trial
ATA188, Atara Biotherapeutics’ investigative T-cell immunotherapy, is safe, well tolerated, and able to ease disability and improve exercise…
Bafiertam, Oral Relapsing MS Therapy, Arrives in US
Bafiertam (monomethyl fumarate), a bioequivalent of Tecfidera to treat relapsing forms of multiple sclerosis (MS), is now available…
MS Patients Who Interact With Health Information More Likely to Adopt Healthy Lifestyle
Multiple sclerosis (MS) patients who interact with different sources of health information are more likely to adopt and maintain…
SomaCeuticals Acquires Rights to Formula Targeting Lesions in MS
SomaCeuticals, a subsidiary of AngioSoma, has acquired exclusive global rights to a patented formula that aims to…
Youthful Obesity May Account for 14% of MS Cases in US by 2035
The number of new cases of multiple sclerosis (MS) possibly due to obesity in childhood and adolescence could rise…
#MSVirtual2020 – MRI Changes Can Reflect Function in Progressive MS, Study Says
Certain MRI measures of the brain and spinal cord directly associate with functional improvements in people with progressive…
Sanofi to Acquire Principia Biopharma in $3.6 Billion Transaction
In a $3.68 billion transaction, Sanofi is preparing to acquire Principia Biopharma, a biopharmaceutical company focused…
CHI3L1 Protein Levels May Mark Neurologic Disability in PPMS, Study Suggests
Levels of a protein linked to inflammation and neurodegeneration in multiple sclerosis (MS) — called chitinase 3-like-1 (CHI3L1)…
Tysabri in Long-term Use Seen to Lessen Relapses, Stabilize Disease
Tysabri (natalizumab) is effective at reducing the frequency of relapses in patients with relapsing-remitting multiple sclerosis (…
UK Health Services Failing MS Patient Needs Under Pandemic, Survey Finds
A vast majority — 7 out of every 10 — healthcare professionals working with multiple sclerosis (MS) patients across…
FDA Will Review Arbaclofen ER, Potential Oral Therapy for MS Spasticity
The U.S. Food and Drug Administration (FDA) has agreed to review  Osmotica Pharmaceuticals‘ amended…
Retina Thickness Can Be Used to Identify MS Patients with Progressive Disease, Study Suggests
The thickness of two layers of nerve cells forming the back of the eye, or retina, can be…
High Levels of NfL Protein Linked to Disability, Faster Disease Progression in MS
High levels of neurofilament light chain (NfL) protein circulating in the blood of patients with multiple sclerosis (MS)…
University of Sydney Awarded AU$7.1M in Pursuit of Better MS, Mental Health Treatment
The Australian Government’s Medical Research Future Fund (MRFF) has awarded AU$7.1 million (about $4.95 million) to support two projects…
Trial of Cannabis Derivatives in Treating MS Spasticity to Open in Canada
The Multiple Sclerosis Society of Canada and its partner, the Canadian Institutes of Health Research (CIHR), have invested…
B-Cells Infected by Epstein-Barr Virus Linked to MS Relapse Risk in Study
Immune B-cells that proliferate unchecked when infected by the Epstein-Barr virus (EBV) appear to increase the risk of relapses…
Collaborative Project Will Focus on TRPM4 as Potential Therapeutic Target for MS
The German Federal Ministry of Education and Research (BMBF) has granted €1.2 million ($1.35 million) to support a project seeking…